Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Pharmaceuticals has announced the discovery and initiation of IND enabling studies of an anti-OX40 monoclonal antibody, GBR 830.
Subscribe to our email newsletter
Glenmark Biologics Research Centre in La Chaux-de-Fonds, Switzerland, discovered GBR 830.
GBR 830 is a potent therapeutic option for patients suffering from immune pathologies including autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease.
Glenmark Pharmaceuticals biologics president and chief scientific officer Dr. Michael Buschle said at present there are no antagonistic antibodies targeting OX40 in clinical stage of development.
"We are confident that the antibody expertise and product development capabilities of the Switzerland Biologics Research Centre will continue to enrich the Glenmark discovery pipeline," Buschle added.